摘要
目的探讨动脉溶栓联合血管内支架植入在治疗急性脑梗死患者中应用的效果及安全性。方法将62例急性脑梗死患者随机分为支架组和药物组,每组31例。支架组患者在尿激酶动脉溶栓后联合血管内支架植入治疗;药物组在尿激酶动脉溶栓后以常规药物治疗。于术后1、7、14、21d进行NIHSS评分,并综合评定预后及血管再通情况。结果支架组NIHSS评分明显低于药物组,显效率、有效率和血管再通率分别为80.7%、100.0%和100.0%,明显高于药物组的38.7%、61.3%和61.3%(P<0.05)。结论动脉溶栓联合血管内支架植入在治疗急性脑梗死患者中应用,效果确切,并发症少,是一种安全有效的治疗方法。
Objective To discuss the safety and efficacy of intra-arterial thrombolytic therapy in combination with endovascular sent implantation on the patients of acute cerebral infarction. Methods 62 patients with acute cerebral Infarction were divided into two groups,the stent group and the medicine group,31 cases in each group.The patients in the stent group were treated with endovascular stent therapy after intra-arterial thrombolysis therapy, while the patients in the medicine group were treated with drug.The NIHSS（National Institutes of Health Stroke Scale）scores ,the Comprehensive evaluation of the prognosis and the condition of recanalization of blood vessel were evaluated on the 1st day,Tth,14th as well as 21th day after PTA. Results The scores of NIHSS in the stent group were lowered than the medicine group.The significant efficiency was 80.7%,the effective rate was 100.0%and the reunobstructed rate was 100.0% in the stent group,were significantly higher than that of drug group,when they were 38.7%,61.3% and 61.3%（P 〈 0.05）. Conclusion The combined therapy of acute cerebral infarction with intra-arterial thrombolytic and endovascular sent implantation is more effective and safer,it may keep minimize the adverse effects.
出处
《中国医药科学》
2014年第11期9-12,16,共5页
China Medicine And Pharmacy
基金
广西壮族自治区卫生厅自筹经费科研课题(Z2012735)
关键词
尿激酶
动脉溶栓
血管内支架植入
急性脑梗死、
Urokinase
Arterial thrombolysis
Endovascular stent implantation
Acute cerebral infarction
